-
1
-
-
0029092503
-
In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
-
Partaledis, J. A., Yamaguchi, K., Tisdale, M. et al. (1995). In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. Journal of Virology 69, 5228-35.
-
(1995)
Journal of Virology
, vol.69
, pp. 5228-5235
-
-
Partaledis, J.A.1
Yamaguchi, K.2
Tisdale, M.3
-
2
-
-
0029133978
-
Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors
-
Tisdale, M., Myers, R. E., Maschera, B. et al. (1995). Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrobial Agents and Chemotherapy 39, 1704-10.
-
(1995)
Antimicrobial Agents and Chemotherapy
, vol.39
, pp. 1704-1710
-
-
Tisdale, M.1
Myers, R.E.2
Maschera, B.3
-
3
-
-
0036174439
-
Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: Selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors
-
Maguire, M., Shortino, D., Klein, K. et al. (2002). Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrobial Agents and Chemotherapy 46, 731-8.
-
(2002)
Antimicrobial Agents and Chemotherapy
, vol.46
, pp. 731-738
-
-
Maguire, M.1
Shortino, D.2
Klein, K.3
-
4
-
-
0038369071
-
HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study
-
Ait-Khaled, M., Rakik, A., Griffin, P. et al. (2003). HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Antiviral Therapy 8, 111-20.
-
(2003)
Antiviral Therapy
, vol.8
, pp. 111-120
-
-
Ait-Khaled, M.1
Rakik, A.2
Griffin, P.3
-
5
-
-
4243521639
-
Impact on fitness conferred by amprenavir resistance mutations
-
In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 2001. Abstract I-1766, American Society for Microbiology, Washington, DC, USA
-
Harris, W., Randall, S., Manohitharajah, V. et al. (2001). Impact on fitness conferred by amprenavir resistance mutations. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 2001. Abstract I-1766, p. 338. American Society for Microbiology, Washington, DC, USA.
-
(2001)
, pp. 338
-
-
Harris, W.1
Randall, S.2
Manohitharajah, V.3
-
6
-
-
0037012979
-
Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity
-
Prado, J. G., Wrin, T., Beauchaine, J. et al. (2002). Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 16, 1009-17.
-
(2002)
AIDS
, vol.16
, pp. 1009-1017
-
-
Prado, J.G.1
Wrin, T.2
Beauchaine, J.3
-
7
-
-
24444466690
-
Plasma trough levels correlate with distinct genetic mechanisms during the development of amprenavir resistance
-
In Program and Abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 2001. Abstract 465, Foundation for Retrovirology and Human Health, Alexandria, VA, USA
-
Elston, R., Randall, S., Myers, R. et al. (2001). Plasma trough levels correlate with distinct genetic mechanisms during the development of amprenavir resistance. In Program and Abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 2001. Abstract 465, p. 182. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
-
(2001)
, pp. 182
-
-
Elston, R.1
Randall, S.2
Myers, R.3
-
8
-
-
0038360368
-
GW433908 in ART naive patients: Absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen
-
In Program and Abstracts of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, USA, 2003. Abstract 598, Foundation for Retrovirology and Human Health, Alexandria, VA, USA
-
MacManus, S., Yates, P., White, S. et al. (2003). GW433908 in ART naive patients: absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen. In Program and Abstracts of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, USA, 2003. Abstract 598, p. 271. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
-
(2003)
, pp. 271
-
-
MacManus, S.1
Yates, P.2
White, S.3
-
9
-
-
0031849665
-
In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
-
Carrillo, A., Stewart, K. D., Sham, H. L. et al. (1998). In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. Journal of Virology 72, 7532-41.
-
(1998)
Journal of Virology
, vol.72
, pp. 7532-7541
-
-
Carrillo, A.1
Stewart, K.D.2
Sham, H.L.3
-
10
-
-
0141661555
-
Multiple pathways to resistance to ABT-378 observed by in vitro selection
-
In Program and Abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections, Boston, USA, 1999. Abstract 117, Foundation for Retrovirology and Human Health, Alexandria, VA, USA
-
Mo, H., Chernyavskiy, T., Lu, L. et al. (1999). Multiple pathways to resistance to ABT-378 observed by in vitro selection. In Program and Abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections, Boston, USA, 1999. Abstract 117, p. 89. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
-
(1999)
, pp. 89
-
-
Mo, H.1
Chernyavskiy, T.2
Lu, L.3
-
11
-
-
0141550180
-
Patterns of protease inhibitor cross-resistance in viral isolates with reduced susceptibility to ABT-378
-
In Program and Abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 2001. Abstract 452, Foundation for Retrovirology and Human Health, Alexandria, VA, USA
-
Brun, S., Kempf, D., Isaacson, J. et al. (2001). Patterns of protease inhibitor cross-resistance in viral isolates with reduced susceptibility to ABT-378. In Program and Abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 2001. Abstract 452, p. 178. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
-
(2001)
, pp. 178
-
-
Brun, S.1
Kempf, D.2
Isaacson, J.3
-
12
-
-
0141773489
-
Comparative incidence and temporal accumulation of PI and NRTI resistance in HIV-infected subjects receiving lopinavir or nelfinavir as initial therapy
-
In Program and Abstracts of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, USA, 2003. Abstract 600, Foundation for Retrovirology and Human Health, Alexandria, VA, USA
-
Kempf, D., King, M., Moseley, J. et al. (2003). Comparative incidence and temporal accumulation of PI and NRTI resistance in HIV-infected subjects receiving lopinavir or nelfinavir as initial therapy. In Program and Abstracts of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, USA, 2003. Abstract 600, p. 272. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
-
(2003)
, pp. 272
-
-
Kempf, D.1
King, M.2
Moseley, J.3
-
13
-
-
0038543353
-
Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir and atazanavir in a panel of clinical samples
-
Schnell, T., Schmidt, B., Moschik, G. et al. (2003). Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir and atazanavir in a panel of clinical samples. AIDS 17, 1258.
-
(2003)
AIDS
, vol.17
, pp. 1258
-
-
Schnell, T.1
Schmidt, B.2
Moschik, G.3
-
14
-
-
0033743891
-
Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors
-
Schmidt, B., Korn, K., Moschik, B. et al. (2000). Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors. Antimicrobial Agents and Chemotherapy 44, 3213-6.
-
(2000)
Antimicrobial Agents and Chemotherapy
, vol.44
, pp. 3213-3216
-
-
Schmidt, B.1
Korn, K.2
Moschik, B.3
-
15
-
-
0032750954
-
Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
-
Race, E., Dam, E., Obry, V. et al. (1999). Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 13, 2061-8.
-
(1999)
AIDS
, vol.13
, pp. 2061-2068
-
-
Race, E.1
Dam, E.2
Obry, V.3
-
16
-
-
0036387141
-
Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia
-
Paulsen, D., Liao, Q., Fusco, G. et al. (2002). Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. AIDS Research and Human Retroviruses 18, 1011-9.
-
(2002)
AIDS Research and Human Retroviruses
, vol.18
, pp. 1011-1019
-
-
Paulsen, D.1
Liao, Q.2
Fusco, G.3
-
17
-
-
0036720761
-
Human Immunodeficiency Virus Type I genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor experienced patients
-
Masquelier, B., Breilh, D., Neau, D. et al. (2002). Human Immunodeficiency Virus Type I genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor experienced patients. Antimicrobial Agents and Chemotherapy 46, 2926-32.
-
(2002)
Antimicrobial Agents and Chemotherapy
, vol.46
, pp. 2926-2932
-
-
Masquelier, B.1
Breilh, D.2
Neau, D.3
-
18
-
-
0002583843
-
Differential impact of specific key mutations in HIV protease on phenotypic susceptibility to amprenavir and lopinavir
-
Elston, R., Wolfram, J., Richards, N. et al. (2001). Differential impact of specific key mutations in HIV protease on phenotypic susceptibility to amprenavir and lopinavir. Antiviral Therapy 6, Suppl. 1, 53-5.
-
(2001)
Antiviral Therapy
, vol.6
, Issue.SUPPL. 1
, pp. 53-55
-
-
Elston, R.1
Wolfram, J.2
Richards, N.3
-
19
-
-
0007361104
-
Amprenavir genotype resistance profile in protease inhibitor multi-experienced patients
-
Yvon, A., Descamps, D., Delaguerre, C. et al. (1999). Amprenavir genotype resistance profile in protease inhibitor multi-experienced patients. Antiviral Therapy 4, Suppl. 1, 29.
-
(1999)
Antiviral Therapy
, vol.4
, Issue.SUPPL. 1
, pp. 29
-
-
Yvon, A.1
Descamps, D.2
Delaguerre, C.3
-
20
-
-
24444450666
-
Quantitation of lopinavir resistance and cross-resistance and phenotypic contribution of mutations shared with other protease inhibitors
-
In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 2001. Abstract I-1769, American Society for Microbiology, Washington, DC, USA
-
Harrigan, P. R., Van Den Eynde, C. & Larder, B. (2001). Quantitation of lopinavir resistance and cross-resistance and phenotypic contribution of mutations shared with other protease inhibitors. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 2001. Abstract I-1769, p. 338. American Society for Microbiology, Washington, DC, USA.
-
(2001)
, pp. 338
-
-
Harrigan, P.R.1
Van Den Eynde, C.2
Larder, B.3
-
21
-
-
0034909925
-
Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients
-
Kempf, D. J., Isaacson, J. D., King, M. S. et al. (2001). Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. Journal of Virology 75, 7462-9.
-
(2001)
Journal of Virology
, vol.75
, pp. 7462-7469
-
-
Kempf, D.J.1
Isaacson, J.D.2
King, M.S.3
-
22
-
-
0036768328
-
Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-infected patients receiving lopinavir/ritonavir therapy
-
Kempf, D. J., Isaacson, J. D., King, M. S. et al. (2002). Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-infected patients receiving lopinavir/ritonavir therapy. Antiviral Therapy 7, 165-74.
-
(2002)
Antiviral Therapy
, vol.7
, pp. 165-174
-
-
Kempf, D.J.1
Isaacson, J.D.2
King, M.S.3
-
23
-
-
0141438655
-
Influence of genotypic resistance on the viral load response of 167 patients on lopinavir/r (LPV/r) including an analysis of new protease inhibitor resistant mutations in 21 patients who failed
-
In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February, 2002. Abstract 560-T, Foundation for Retrovirology and Human Health, Alexandria, VA, USA
-
Loutfy, M., Thompson, C., Trpeski, M. et al. (2002). Influence of genotypic resistance on the viral load response of 167 patients on lopinavir/r (LPV/r) including an analysis of new protease inhibitor resistant mutations in 21 patients who failed. In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February, 2002. Abstract 560-T, p. 261. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
-
(2002)
, pp. 261
-
-
Loutfy, M.1
Thompson, C.2
Trpeski, M.3
-
24
-
-
0008860323
-
Identification of individual mutations in HIV protease associated with virological response to lopinavir/ritonavir therapy
-
Calvez, V., Cohen-Codar, I., Marcelin, A. G. et al. (2001). Identification of individual mutations in HIV protease associated with virological response to lopinavir/ritonavir therapy. Antiviral Therapy 6, Suppl. 1, 64-5.
-
(2001)
Antiviral Therapy
, vol.6
, Issue.SUPPL. 1
, pp. 64-65
-
-
Calvez, V.1
Cohen-Codar, I.2
Marcelin, A.G.3
-
25
-
-
0003321265
-
Quantitative estimate of the effect of individual baseline mutations in HIV protease on the virologic response to lopinavir/ritonavir therapy in heavily antiretroviral-experienced patients
-
In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February, 2002. Abstract 559-T, Foundation for Retrovirology and Human Health, Alexandria, VA, USA
-
Isaacson, J., Kempf, D., Calvez, V. et al. (2002). Quantitative estimate of the effect of individual baseline mutations in HIV protease on the virologic response to lopinavir/ritonavir therapy in heavily antiretroviral-experienced patients. In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February, 2002. Abstract 559-T, p. 260. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
-
(2002)
, pp. 260
-
-
Isaacson, J.1
Kempf, D.2
Calvez, V.3
-
26
-
-
0141438657
-
Genotypic predictors of response to lopinavir/ritonavir in clinical practice
-
Rice, H., Nadler, J., Schaenman, J. et al. (2003). Genotypic predictors of response to lopinavir/ritonavir in clinical practice. Antiviral Therapy 8, Suppl. 3, 169.
-
(2003)
Antiviral Therapy
, vol.8
, Issue.SUPPL. 3
, pp. 169
-
-
Rice, H.1
Nadler, J.2
Schaenman, J.3
-
27
-
-
0141773486
-
I84A and I84C mutations in protease confer high level resistance to protease inhibitors and impair replication capacity
-
Mo, H., Parkin, N., Stewart, K. D. et al. (2003). I84A and I84C mutations in protease confer high level resistance to protease inhibitors and impair replication capacity. Antiviral Therapy 8, Suppl. 3, 56.
-
(2003)
Antiviral Therapy
, vol.8
, Issue.SUPPL. 3
, pp. 56
-
-
Mo, H.1
Parkin, N.2
Stewart, K.D.3
-
28
-
-
0141550178
-
Emergence of a novel lopinavir resistance mutation at codon 47 correlates with ARV utilization
-
Kagan, R. M., Shenderovich, M., Ramnarayan, K. & Heseltine, P. N. R. (2003). Emergence of a novel lopinavir resistance mutation at codon 47 correlates with ARV utilization. Antiviral Therapy 8, Suppl. 3, 54.
-
(2003)
Antiviral Therapy
, vol.8
, Issue.SUPPL. 3
, pp. 54
-
-
Kagan, R.M.1
Shenderovich, M.2
Ramnarayan, K.3
Heseltine, P.N.R.4
-
29
-
-
0000825264
-
A genotypic sensitivity score for amprenavir based on genotype at baseline and virological response
-
Descamps, D., Masquelier, B., Mamet, J. P. et al. (2001). A genotypic sensitivity score for amprenavir based on genotype at baseline and virological response. Antiviral Therapy 6, Suppl. 1, 103.
-
(2001)
Antiviral Therapy
, vol.6
, Issue.SUPPL. 1
, pp. 103
-
-
Descamps, D.1
Masquelier, B.2
Mamet, J.P.3
-
30
-
-
0037308542
-
Genotypic inhibitory quotient as a predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients
-
Marcelin, A. G., Lamotte, C., Delaugerre, C. et al. (2003). Genotypic inhibitory quotient as a predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrobial Agents and Chemotherapy 47, 594-600.
-
(2003)
Antimicrobial Agents and Chemotherapy
, vol.47
, pp. 594-600
-
-
Marcelin, A.G.1
Lamotte, C.2
Delaugerre, C.3
-
31
-
-
0038555736
-
Improving lopinavir genotype algorithm through phenotype correlations: Novel mutation patterns and amprenavir cross-resistance
-
Parkin, N. T., Chappey, C. & Petropoulos, C. J. (2003). Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 17, 955-61.
-
(2003)
AIDS
, vol.17
, pp. 955-961
-
-
Parkin, N.T.1
Chappey, C.2
Petropoulos, C.J.3
-
32
-
-
0038238324
-
Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance
-
De Luca, A., Cingolani, A., Di Giambenedetto, S. et al. (2003). Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. Journal of Infectious Diseases 187, 1934-43.
-
(2003)
Journal of Infectious Diseases
, vol.187
, pp. 1934-1943
-
-
De Luca, A.1
Cingolani, A.2
Di Giambenedetto, S.3
|